Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.
Cho, Y.S., Angove, H., Brain, C., Chen, C.H., Cheng, H., Cheng, R., Chopra, R., Chung, K., Congreve, M., Dagostin, C., Davis, D.J., Feltell, R., Giraldes, J., Hiscock, S.D., Kim, S., Kovats, S., Lagu, B., Lewry, K., Loo, A., Lu, Y., Luzzio, M., Maniara, W., McMenamin, R., Mortenson, P.N., Benning, R., O'Reilly, M., Rees, D.C., Shen, J., Smith, T., Wang, Y., Williams, G., Woolford, A.J., Wrona, W., Xu, M., Yang, F., Howard, S.(2012) ACS Med Chem Lett 3: 445-449
- PubMed: 24900493 
- DOI: https://doi.org/10.1021/ml200241a
- Primary Citation of Related Structures:  
4AUA, 4EZ5 - PubMed Abstract: 
Herein, we describe the discovery of potent and highly selective inhibitors of both CDK4 and CDK6 via structure-guided optimization of a fragment-based screening hit. CDK6 X-ray crystallography and pharmacokinetic data steered efforts in identifying compound 6, which showed >1000-fold selectivity for CDK4 over CDKs 1 and 2 in an enzymatic assay. Furthermore, 6 demonstrated in vivo inhibition of pRb-phosphorylation and oral efficacy in a Jeko-1 mouse xenograft model.
Organizational Affiliation: 
Novartis Institutes for Biomedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.